According to analysts at Vantage Market Research, the Global Bortezomib Market size is worth USD 25.1 Million in 2024 and is projected to reach USD 41.16 Million by 2035, growing at a CAGR (Compound Annual Growth Rate) of 4.6% from 2024 to 2035. Key trends of market includerising adoption in cancer treatment, advancements in combination therapies, increasing research on side-effect mitigation, and expanding market access in emerging regions for oncology care.

Market Overview

Bortezomib is a cancer treatment drug primarily used for blood cancers like multiple myeloma and mantle cell lymphoma. It belongs to the proteasome inhibitor class, which works by blocking proteasomes cellular structures responsible for protein breakdown. Cancer affects plasma cells responsible for immune defense, predominantly impacts older adults, with age, genetics, and family history being significant risk factors. The disease is rare in individuals under 40 but becomes increasingly common with age. As global life expectancy rises, the aging population expands, leading to a larger pool of individuals susceptible to multiple myeloma. This growing prevalence drives demand for effective treatment options like bortezomib, a widely prescribed drug for the disease. Multiple myeloma, if untreated, can result in severe complications such as bone lesions, marrow suppression, and fatality. The increased disease burden, particularly in aging populations with improved healthcare access, has significantly boosted the demand for bortezomib in regions like North America and Europe over the past decade.

Asia Pacific and Latin America are experiencing a rise in blood cancer cases, including multiple myeloma, due to aging populations and lifestyle changes. Historically, low treatment rates in these areas were attributed to economic constraints and limited access to advanced therapies. However, increasing healthcare investments, improved medical awareness, and broader health insurance coverage are enabling greater access to novel treatments like bortezomib. These markets also offer advantages such as less stringent regulatory environments and fewer price controls compared to developed regions.

GSK’s DREAMM-7 Trial Shows Belantamab Mafodotin Outperforms Daratumumab in Relapsed or Refractory Multiple Myeloma

• In November 2024, GSK plc reported positive interim results from the DREAMM-7 Phase III trial. The study demonstrated that belantamab mafodotin, when combined with bortezomib and dexamethasone (BorDex), significantly improved progression-free survival (PFS) compared to daratumumab plus BorDex in patients with relapsed or refractory multiple myeloma. Additionally, the trial showed a strong trend toward enhanced overall survival (OS), with a nominal p-value of < 0.0005, and OS follow-up is still ongoing

Key Takeaways from the Report

• In 2024, North America dominated the market  with 46.5% market share in 2024. Market is driven by a well-established healthcare system, a high prevalence of multiple myeloma, and supportive reimbursement policies
• Based on the Types, the 1mg category accounted for significant market share in 2024. 1mg dosage is commonly prescribed due to its effectiveness in treating multiple myeloma and mantle cell lymphoma
• In 2024, by Applications, Multiple Myeloma dominated the market with significant market share of 55.5%. The segment is driven by its position as the second most common hematologic cancer after non-Hodgkin's lymphoma
• In 2024, based on Dosage, Community Injection dominated the market with significant market share. 
• In 2024, by End-Users, Hospital dominated the market with market share of 51.5%. This segment is expected to grow at the fastest rate due to its suitability for administering chemotherapy treatments

Top Companies

• Dr. Reddy's Laboratories
• TAPI Teva
• Chem-Stone (Guangzhou)
• Gland Pharma
• Pfizer
• Scion Pharmaceuticals
• Meitheal Pharmaceuticals
• Vinkem Labs
• Hikma Pharmaceuticals
• Farmhispania Group
• Shilpa Medicare
• Hubei Honch Pharmaceutical
• Novartis International AG
• Teva Pharmaceuticals
• Chengdu Aslee Biopharmaceuticals
• NATCO Pharma

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

FDA Approves Darzalex Faspro Combination Therapy for Newly Diagnosed Multiple Myeloma Patients Eligible for ASCT

• In July 30, 2024, the U.S. FDA approved the combination of daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Research & Development, LLC) with bortezomib, lenalidomide, and dexamethasone for use in induction and consolidation therapy for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant (ASCT)

About Vantage Market Research:

We, at Vantage Market Research, provide quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map out constellation of opportunities for their businesses. We, as a competitive intelligence market research and consulting firm provide end to end solutions to our client enterprises to meet their crucial business objectives. Our clientele base spans across 70% of Global Fortune 500 companies. The company provides high quality data and market research services. The company serves various enterprises and clients in a wide variety of industries. The company offers detailed reports on multiple industries including Chemical Materials and Energy, Food and Beverages, Healthcare Technology, etc. The company’s experienced team of Analysts, Researchers, and Consultants use proprietary data sources and numerous statistical tools and techniques to gather and analyse information.